Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cholangiocarcinoma of the Gallbladder: early-phase trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Cholangiocarcinoma of the Gallbladder: 2 US clinical trials tracked, none currently recruiting.
Cholangiocarcinoma of the Gallbladder is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 1 of these trials.
Enrollment posture brief
Registry condition cholangiocarcinoma-of-the-gallbladder
OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Cholangiocarcinoma of the Gallbladder has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cholangiocarcinoma of the Gallbladder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cholangiocarcinoma of the Gallbladder is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
NCT00028496
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Mayo Clinic
NCT00949949
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Cholangiocarcinoma of the Gallbladder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cholangiocarcinoma of the Gallbladder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cholangiocarcinoma of the Gallbladder page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Cholangiocarcinoma of the Gallbladder trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Mayo Clinic sponsors the most Cholangiocarcinoma of the Gallbladder trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cholangiocarcinoma of the Gallbladder condition card totals 2 registered trials; most-linked intervention recombinant fowlpox-CEA(6D)/TRICOM vaccine; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.